80个药品将在国内停止生产销售,超一半为外资公司产品

动脉网
Oct 20, 2025

10月15日,国家药品监督管理局决定注销80个药品注册证书,这些药品后续将在国内停止生产销售,其中超55%为外资公司产品,包括MacroGenics,Inc.的马吉妥昔单抗注射液、BioMarin International Limited的依洛硫酸酯酶α注射液等。马吉妥昔单抗是再鼎医药引进的单克隆抗体,2023年9月获批,但同年第四季度再鼎医药就决定停止其开发。利司那肽注射液是赛诺菲旗下的降糖药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10